New drug combo targets hard-to-treat lung cancer gene
NCT ID NCT03170206
First seen Feb 20, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This early-phase trial tested a combination of two targeted drugs (palbociclib and binimetinib) in 34 people with advanced lung cancer that has a specific KRAS gene change. The main goal was to find the safest dose and check for early signs of tumor control. While not a cure, this approach aims to manage the disease in patients who have few other options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.